LifeCodexx AG – Research & Development

At the forefront of this field in Europe

In 2012, the PrenaTest® was the first blood test in all of Europe to employ this new, risk-free test method. Since then, we have continued to further develop it. Today, the test detects the most common trisomies as well as deviations in the number of sex chromosomes and identifies the gender of the fetus. We have also drastically reduced the wait time for test results and have developed a method for measuring the level of cell-free fetal DNA in the maternal blood, which quickly enables us to initially determine whether a blood sample is able to be analyzed at all. This also saves valuable time. Of course, we will also endeavor to remain at the forefront of this field well into the future. Many innovative developments are already underway.

 

Aug. 2012Market launch of the PrenaTest® for the determination of fetal trisomy 21 from the twelfth week of pregnancy (12+0)
Feb. 2013Expansion of the PrenaTest® to determine fetal trisomies 21, 18, and 13
Jul. 2013PrenaTest® becomes available from the ninth week of pregnancy (9+0) QuantYfeX® assay is introduced for determination of cffDNA levels
Oct. 2013Introduction of PrenaTest®express – results in one week
Feb. 2014PrenaTest® expanded to include twin pregnancies
Jun. 2014PrenaTest® expanded to include the determination of gonosomal aneuploidies
2015 PCR-based NIPT assay
Dec. 2016Innovative methylation-specific qPCR assay for the detection of fetal trisomy 21 (qNIPT)

 

Print Friendly
top